Ignite Creation Date:
2024-05-06 @ 11:23 AM
Last Modification Date:
2024-10-26 @ 12:44 PM
Study NCT ID:
NCT03504163
Status:
RECRUITING
Last Update Posted:
2024-06-25
First Post:
2018-04-11
Brief Title:
Pembrolizumab MK-3475 and Bacillus Calmette-Guérin BCG as First-Line Treatment for High-Risk T1 Non-Muscle-Invasive Bladder Cancer NMIBC and High-Grade Non-Muscle-Invasive Upper Tract Urothelial Carcinoma NMI-UTUC
Sponsor:
Memorial Sloan Kettering Cancer Center
Organization:
Memorial Sloan Kettering Cancer Center
Organization Data
Organization:
Memorial Sloan Kettering Cancer Center
Class:
OTHER
Study ID:
17-602
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Memorial Sloan Kettering Cancer Center
Lead Sponsor Class:
OTHER
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| Merck Sharp Dohme LLC | INDUSTRY |